GPX4 and non-small cell lung carcinoma: Ni et al. [31] demonstrated that the inhibition of mTORC1 overcame NSCLC resistance to lapatinib by promoting ferroptosis via the downregulation of GPX4 and the enhancement of intracellular ROS, MDA, and Fe2+ levels.